Instacart vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ: CART grocery marketplace at $3.22B FY2024 revenue with 1,400+ retailers and $1B+ Carrot Ads business; Caper Cart AI smart cart competing with DoorDash and Walmart+ for online grocery and CPG advertising.
About
Instacart (Maplebear Inc.) is a San Francisco-based grocery technology company — listed on NASDAQ (NASDAQ: CART) following its September 2023 IPO at a $9.9 billion valuation — operating the largest US online grocery marketplace with partnerships with 1,400+ retailers and 85,000+ stores (Kroger, Costco, Albertsons, Publix, Aldi, Whole Foods), 600,000+ shoppers who fulfill same-day delivery and pickup orders, and advertising technology (Instacart Ads) that enables consumer packaged goods brands to reach shoppers at the moment of purchase intent. Instacart generated $3.22 billion in total revenue in fiscal year 2024 (+11% year-over-year) and is developing Caper Cart (AI-powered smart shopping cart technology with integrated computer vision scanning), Carrot Ads (retail media network for CPG brands), and Instacart Platform (white-label grocery e-commerce infrastructure) as its technology expansion beyond the core marketplace. Founded in 2012 by Apoorva Mehta, who famously ordered beer as the first Instacart delivery to test the service.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.